Biotech News

Phathom Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

Phathom Pharmaceuticals (PHAT)Phathom PharmaceuticalsEarnings

Over 2 million total VOQUEZNA® prescriptions filled through October 16, 2026 Q3 2026 net revenues of $84.7 million increased 71% vs. Q3 2025 and 14% vs. Q2 2026 Generated positive operating cash flow for the second consecutive quarter Reaffirmed full-year 2026 financial guidance Conference call and

Related news

Phathom Pharmaceuticals

Gastrointestinal Medicines Phathom Pharmaceuticals develops and commercializes treatments for acid-related gastrointestinal diseases. It holds U.S., European and Canadian rights to vonoprazan, a potassium-competitive acid blocker. VOQUEZNA Franchise VOQUEZNA is marketed in the United States for heartburn associated with non-erosive...

Recent company news

Stock data

Close
5.08 USD
Market cap
769.64M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States